Jing Wu, PhD, is a health economist and Professor at the School of Pharmaceutical Science and Technology, Tianjin University. She currently serves as Chair of the Pharmacoeconomics Professional Committee of the Chinese Pharmaceutical Association and as Vice Chair of the Pharmacoeconomics Professional Committees of the China Health Insurance Research Association and the Chinese Research Hospital Association.
Dr. Wu has nearly 20 years of experience in health economics and pharmacoeconomics research and education. Her work focuses on health policy evaluation, pharmacoeconomic assessment, real-world data analysis, and the measurement of health-related quality of life and health utilities, with a strong emphasis on supporting evidence-based reimbursement and policy decision-making. She received her PhD in Pharmacoeconomics in 2007 through a joint doctoral program between Shenyang Pharmaceutical University and Peking University. In 2013, she was a visiting scholar at the Schaeffer Center for Health Policy & Economics at the University of Southern California, where she further strengthened her expertise in applied economic evaluation and health policy analysis.
Dr. Wu has published more than 100 peer-reviewed articles in leading international journals, including BMJ, JAMA Pediatrics, Social Science & Medicine, Value in Health, and PharmacoEconomics. She has led several nationally funded research projects, including a Major Project supported by the National Social Science Fund of China and three projects funded by the National Natural Science Foundation of China. She has also contributed to authoritative textbooks in pharmacoeconomics.
A core component of Dr. Wu’s contribution is her leadership in methodological development and standard-setting. She serves as Editor-in-Chief of the China Guidelines for Pharmacoeconomic Evaluations 2025 and was a principal author of the China Guidelines for Pharmacoeconomic Evaluations 2020 and the Guideline Manual 2022, playing a key role in advancing the standardization of pharmacoeconomic evaluation in China. She also serves as a national healthcare policy think tank expert, providing strategic input on reimbursement policy, health technology assessment, and health system reform.
Dr. Wu is currently President-Elect of the ISPOR Beijing Chapter. Her international service includes roles as Co-Chair of the ISPOR Asia-Pacific Conference Program Committee, Co-Chair of the Abstract Review Committee, Chair of the ISPOR Asia-Pacific Emerging Scholars Working Group, and member of the ISPOR Health Science Policy Council. Since 2017, she has founded the China Young Scholars Forum on Pharmacoeconomics to support academic exchange and early-career development.
Vision Statement
It is an honor to be a candidate for the ISPOR Board of Directors. ISPOR plays a vital global role in advancing excellence in pharmacoeconomics and health outcomes research (HEOR) and in promoting evidence-informed health decision-making across diverse health systems. Its commitment to scientific rigor, transparency, and policy relevance is increasingly important as health systems worldwide face growing complexity and resource constraints.
My long-standing engagement with ISPOR - including service as Asia-Pacific Associate Editor for Value in Health Regional Issues, President-Elect of the ISPOR Beijing Chapter, and participation in editorial and regional scientific activities - has deepened my understanding of ISPOR’s unique role as a global platform connecting research, policy, and practice. These experiences have reinforced my appreciation of ISPOR’s ability to set international scientific standards while respecting regional diversity in health system contexts.
The Asia-Pacific region, including China, is undergoing rapid development in health technology assessment (HTA), pharmacoeconomics, and the application of real-world evidence in reimbursement and policy decisions. As a contributor to national pharmacoeconomic guidelines and an advisor to public-sector decision-makers, I have worked at the interface of methodological development and policy implementation. If elected, I would bring this regional perspective to ISPOR’s global dialogue, supporting the organization’s mission to promote high-quality, internationally consistent, and policy-relevant evidence.
My priorities as a Board member would include strengthening cross-regional collaboration, encouraging the dissemination of high-quality HEOR research from Asia, and supporting capacity building - particularly for early-career researchers - so that emerging expertise can contribute meaningfully to global evidence generation. I also support ISPOR’s continued leadership in promoting the transparent and rigorous use of real-world data and digital analytics to enhance the quality and credibility of health decision-making.
Serving on the ISPOR Board of Directors would be both an honor and a responsibility. If elected, I am committed to working collaboratively with colleagues worldwide to advance ISPOR’s mission and to foster a more connected, inclusive, and scientifically rigorous global HEOR community.